Pharmaceutical Executive April 2015

April 2015 | Volume 34, Issue 4
From the Editor
Learnings gleaned from our annual EAB meeting, hosted this year by Dr. David Nash, Dean of the Thomas Jefferson University School of Population Health.
Columns
Casey McDonald asks, is it time to view cell therapy companies differently on Wall Street-even distinct from biotech?
David Ormesher makes sense of the new cost-containment model and value-for-money conundrums like those in the HCV space.
FDA is under pressure to moderate oversight of pharma advertising and promotion.
The EU’s proposed new study on off-label prescribing is just another way of kicking the subject into the long grass.
Does patient choice matter to antitrust enforcers?
Features
Pharm Exec convened an expert panel on rare disease to highlight the challenges of serving expectant patients in this uniquely complex market access environment.
The task of imitating substantially complex molecular entities offers up a host of new operational questions for pharma, writes Casey McDonald.
Pharm Exec profiles the journey of Healthcare Businesswomen’s Association 2015 Woman of the Year, Denice Torres.
The looming shift to cross-border compliance in Europe puts the spotlight on the evolving role of chief compliance officers.
The task of imitating substantially complex molecular entities offers up a host of new operational questions for pharma.
Special Sponsored Section
By Pharmaceutical Executive Editors
Energy reform may be stealing the headlines in Mexico, but a rising regulatory authority, the beginnings of healthcare reform, and cost-competitive manufacturing are fueling future growth in the country’s pharma industry-for domestic and global players alike.
native1_300x100
lorem ipsum